Condition

Advanced Breast Cancer

ClinicalTrials.gov condition label

Clinical trials243

Recruiting64

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerNCT07310420 · 2026-10-30

A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsNCT07801508 · 2026-09-08

Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion StudyNCT07602907 · 2026-08-04

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerNCT07591090 · 2026-07-17

Timing of ctDNA Testing in Advanced Breast CancerNCT07681323 · 2026-07-08

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerNCT07600164 · 2026-07-06

Decision Support Tool for Patients With Advanced Breast CancerNCT07635147 · 2026-06-17

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsNCT07524322 · 2026-06-01

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerNCT07597629 · 2026-05-25

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerNCT07427394 · 2026-05-06

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast CancerNCT07540533 · 2026-01-20

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast CancerNCT07227831 · 2026-01-16

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentNCT07281833 · 2025-11-27

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersNCT07259226 · 2025-11-14

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid TumorsNCT07130383 · 2025-09-30

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerNCT07180160 · 2025-09-25

Trastuzumab Deruxtecan in Advanced Breast CancerNCT07180264 · 2025-08-28

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast CancerNCT07180082 · 2025-08-28

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerNCT07037199 · 2025-08-18

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer PatientsNCT07405931 · 2025-07-09

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · 2025-06-30

Engage Psychosocial Intervention for Cancer SymptomsNCT06555588 · 2025-06-11

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsNCT06993844 · 2025-06-10

HS-10502 Combination Treatment in Patients With Advanced Solid TumorsNCT06769425 · 2025-05-07

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05

Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29

A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerNCT06638307 · 2024-10-25

Study of DM5167 in Patients With Advanced Solid TumorsNCT07101601 · 2024-10-24

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerNCT06649331 · 2024-10-21

Organoid-based Functional Precision Therapy for Advanced Breast CancerNCT06102824 · 2024-10-01

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast CancerNCT06776861 · 2024-09-24

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorNCT05933395 · 2024-09-23

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast CancerNCT06123988 · 2024-09-09

The COMPASSION StudyNCT06507930 · 2024-09-01

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)NCT06656624 · 2024-08-13

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast CancerNCT06548919 · 2024-08-08

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerNCT06433609 · 2024-08-05

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857 · 2024-07-19

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCNCT06263543 · 2024-06-17

Dalpiciclib in HR+/HER2- ABCNCT06301438 · 2024-05-03

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsNCT06044623 · 2024-04-01

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdNCT06298084 · 2024-03-21

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).NCT06217185 · 2024-01-02

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialNCT06176534 · 2024-01-01

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01

Whole Body MRI in OncologyNCT06895291 · 2023-10-26

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerNCT05949541 · 2023-07-26

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast CancerNCT05876065 · 2023-06-01

RC48-ADC in HER2-low Advanced Breast CancerNCT05831878 · 2023-05-04

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorNCT05536128 · 2022-12-31

SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsNCT05452213 · 2022-10-12

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)NCT05142475 · 2021-11-19

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant DeficiencyNCT04892693 · 2021-05-25

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerNCT04965766 · 2021-05-11

Common interventions

Leading sponsors

MedSIR13 AstraZeneca11 Fudan University7 Novartis Pharmaceuticals7 Pfizer6 Spanish Breast Cancer Research Group5 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University5 CSPC Ouyi Pharmaceutical Co., Ltd.4 Jiangsu HengRui Medicine Co., Ltd.4 The First Affiliated Hospital with Nanjing Medical University4 Wenjin Yin4 Ahon Pharmaceutical Co., Ltd.3 Bristol-Myers Squibb3 Duke University3 Henan Cancer Hospital3

Trial status mix

COMPLETED71

RECRUITING64

UNKNOWN44

ACTIVE_NOT_RECRUITING18

NOT_YET_RECRUITING18

TERMINATED18

WITHDRAWN8

ENROLLING_BY_INVITATION1

SUSPENDED1

Phase mix

PHASE2113

PHASE172

PHASE328

NA16

PHASE44

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.